Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism.
Mishima M et al.
Clinical Case Reports, 2024
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia.
Yang W et al.
Jama Network Open, 2022
PharmVar GeneFocus: CYP3A5.
Rodriguez-Antona C et al.
Clinical Pharmacology and Therapeutics, 2022
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association With Cytochrome P450 3A Polymorphisms.
Wilson RT et al.
American Journal of Epidemiology, 2018
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.
Umamaheswaran G et al.
The Indian Journal of Medical Research, 2014
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
Xu CF et al.
British Journal of Cancer, 2010
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
Mukonzo JK et al.
British Journal of Clinical Pharmacology, 2009
Pharmacogenetics of calcineurin inhibitors in renal transplantation.
Coto E et al.
Transplantation, 2009
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Ekhart C et al.
Pharmacogenetics and Genomics, 2008
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C et al.
Pharmacogenetics and Genomics, 2008
Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls.
Petrova DT et al.
Onkologie, 2007
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M et al.
Pharmacogenetics and Genomics, 2007
Ethnic differences in the distribution of CYP3A5 gene polymorphisms.
Quaranta S et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2006
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Hermann M et al.
Clinical Pharmacology and Therapeutics, 2006
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.
Lee SJ et al.
Journal of Clinical Pharmacology, 2006
Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clinical Pharmacokinetics, 2006
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM et al.
Molecular Diagnosis & Therapy, 2006
CYP3A5 mRNA degradation by nonsense-mediated mRNA decay.
Busi F et al.
Molecular Pharmacology, 2005
CYP3A5 genotypes and risk of oesophageal cancer in two South African populations.
Dandara C et al.
Cancer Letters, 2005
Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).
Atanasova SY et al.
Clinical Biochemistry, 2005
An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore.
Chowbay B et al.
Drug Metabolism Reviews, 2005
Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.
Lee SJ et al.
Pharmacogenetics, 2003
Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
Shih PS et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
CYP3A5 variant allele frequencies in Dutch Caucasians.
van Schaik RH et al.
Clinical Chemistry, 2002
Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.
Hiratsuka M et al.
European Journal of Clinical Pharmacology, 2002
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS et al.
Molecular Pharmacology, 2002
The genetic determinants of the CYP3A5 polymorphism.
Hustert E et al.
Pharmacogenetics, 2001
Genetic polymorphism of cytochrome P450 3A5 in Chinese.
Chou FC et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2001